vs
EXACT SCIENCES CORP（EXAS）与Loews Corporation（L）财务数据对比。点击上方公司名可切换其他公司
EXACT SCIENCES CORP的季度营收约是Loews Corporation的1.1倍（$878.4M vs $827.0M），Loews Corporation净利率更高（48.6% vs -9.8%，领先58.4%），EXACT SCIENCES CORP同比增速更快（23.1% vs 4.8%），Loews Corporation自由现金流更多（$426.0M vs $120.4M），过去两年EXACT SCIENCES CORP的营收复合增速更高（17.4% vs 7.9%）
Exact Sciences是总部位于美国威斯康星州麦迪逊的分子诊断企业，专注于早期癌症检测领域。公司核心产品覆盖结直肠癌筛查与预防场景，其中Cologuard是全球首个获批的结直肠癌粪便DNA检测产品，同时还提供其他多种癌症的筛查服务及精准肿瘤检测解决方案。
Loews Corporation是一家总部位于美国的多元化综合企业集团，旗下子公司业务覆盖财产保险、天然气管道运输、酒店运营、油气勘探生产等核心领域，主要服务北美市场的商业、消费者及工业客户。
EXAS vs L — 直观对比
营收规模更大
EXAS
是对方的1.1倍
$827.0M
营收增速更快
EXAS
高出18.3%
4.8%
净利率更高
L
高出58.4%
-9.8%
自由现金流更多
L
多$305.6M
$120.4M
两年增速更快
EXAS
近两年复合增速
7.9%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $878.4M | $827.0M |
| 净利润 | $-86.0M | $402.0M |
| 毛利率 | 70.1% | — |
| 营业利润率 | -9.4% | 65.4% |
| 净利率 | -9.8% | 48.6% |
| 营收同比 | 23.1% | 4.8% |
| 净利润同比 | 90.1% | 115.0% |
| 每股收益（稀释后） | $-0.45 | $1.93 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收EXASL
| Q4 25 | $878.4M | $827.0M | ||
| Q3 25 | $850.7M | $732.0M | ||
| Q2 25 | $811.1M | $769.0M | ||
| Q1 25 | $706.8M | $846.0M | ||
| Q4 24 | $713.4M | $789.0M | ||
| Q3 24 | $708.7M | $683.0M | ||
| Q2 24 | $699.3M | $711.0M | ||
| Q1 24 | $637.5M | $710.0M |
净利润EXASL
| Q4 25 | $-86.0M | $402.0M | ||
| Q3 25 | $-19.6M | $504.0M | ||
| Q2 25 | $-1.2M | $391.0M | ||
| Q1 25 | $-101.2M | $370.0M | ||
| Q4 24 | $-864.6M | $187.0M | ||
| Q3 24 | $-38.2M | $401.0M | ||
| Q2 24 | $-15.8M | $369.0M | ||
| Q1 24 | $-110.2M | $457.0M |
毛利率EXASL
| Q4 25 | 70.1% | — | ||
| Q3 25 | 68.6% | — | ||
| Q2 25 | 69.3% | — | ||
| Q1 25 | 70.8% | — | ||
| Q4 24 | 69.0% | — | ||
| Q3 24 | 69.4% | — | ||
| Q2 24 | 69.8% | — | ||
| Q1 24 | 70.0% | — |
营业利润率EXASL
| Q4 25 | -9.4% | 65.4% | ||
| Q3 25 | -3.0% | 94.1% | ||
| Q2 25 | -0.3% | 70.1% | ||
| Q1 25 | -13.6% | 60.8% | ||
| Q4 24 | -122.8% | 23.8% | ||
| Q3 24 | -5.6% | 80.5% | ||
| Q2 24 | -3.8% | 71.3% | ||
| Q1 24 | -16.7% | 88.6% |
净利率EXASL
| Q4 25 | -9.8% | 48.6% | ||
| Q3 25 | -2.3% | 68.9% | ||
| Q2 25 | -0.1% | 50.8% | ||
| Q1 25 | -14.3% | 43.7% | ||
| Q4 24 | -121.2% | 23.7% | ||
| Q3 24 | -5.4% | 58.7% | ||
| Q2 24 | -2.3% | 51.9% | ||
| Q1 24 | -17.3% | 64.4% |
每股收益（稀释后）EXASL
| Q4 25 | $-0.45 | $1.93 | ||
| Q3 25 | $-0.10 | $2.43 | ||
| Q2 25 | $-0.01 | $1.87 | ||
| Q1 25 | $-0.54 | $1.74 | ||
| Q4 24 | $-4.69 | $0.87 | ||
| Q3 24 | $-0.21 | $1.82 | ||
| Q2 24 | $-0.09 | $1.67 | ||
| Q1 24 | $-0.60 | $2.05 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $964.7M | $6.0B |
| 总债务越低越好 | — | $8.4B |
| 股东权益账面价值 | $2.4B | $18.7B |
| 总资产 | $5.9B | $86.3B |
| 负债/权益比越低杠杆越低 | — | 0.45× |
8季度趋势，按日历期对齐
现金及短期投资EXASL
| Q4 25 | $964.7M | $6.0B | ||
| Q3 25 | $1.0B | $5.4B | ||
| Q2 25 | $858.4M | $4.5B | ||
| Q1 25 | $786.2M | $4.4B | ||
| Q4 24 | $1.0B | $4.6B | ||
| Q3 24 | $1.0B | $5.2B | ||
| Q2 24 | $946.8M | $4.9B | ||
| Q1 24 | $652.1M | $5.4B |
总债务EXASL
| Q4 25 | — | $8.4B | ||
| Q3 25 | — | $8.4B | ||
| Q2 25 | — | $7.9B | ||
| Q1 25 | — | $8.4B | ||
| Q4 24 | — | $8.9B | ||
| Q3 24 | — | $8.8B | ||
| Q2 24 | — | $8.6B | ||
| Q1 24 | — | $8.4B |
股东权益EXASL
| Q4 25 | $2.4B | $18.7B | ||
| Q3 25 | $2.5B | $18.3B | ||
| Q2 25 | $2.5B | $17.5B | ||
| Q1 25 | $2.4B | $17.2B | ||
| Q4 24 | $2.4B | $17.1B | ||
| Q3 24 | $3.2B | $17.4B | ||
| Q2 24 | $3.2B | $16.4B | ||
| Q1 24 | $3.1B | $16.2B |
总资产EXASL
| Q4 25 | $5.9B | $86.3B | ||
| Q3 25 | $5.9B | $85.9B | ||
| Q2 25 | $5.8B | $84.7B | ||
| Q1 25 | $5.7B | $83.1B | ||
| Q4 24 | $5.9B | $81.9B | ||
| Q3 24 | $6.7B | $83.6B | ||
| Q2 24 | $6.7B | $81.1B | ||
| Q1 24 | $6.4B | $80.9B |
负债/权益比EXASL
| Q4 25 | — | 0.45× | ||
| Q3 25 | — | 0.46× | ||
| Q2 25 | — | 0.45× | ||
| Q1 25 | — | 0.49× | ||
| Q4 24 | — | 0.52× | ||
| Q3 24 | — | 0.51× | ||
| Q2 24 | — | 0.52× | ||
| Q1 24 | — | 0.52× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $151.7M | $617.0M |
| 自由现金流经营现金流 - 资本支出 | $120.4M | $426.0M |
| 自由现金流率自由现金流/营收 | 13.7% | 51.5% |
| 资本支出强度资本支出/营收 | 3.6% | 23.1% |
| 现金转化率经营现金流/净利润 | — | 1.53× |
| 过去12个月自由现金流最近4个季度 | $356.8M | $2.7B |
8季度趋势，按日历期对齐
经营现金流EXASL
| Q4 25 | $151.7M | $617.0M | ||
| Q3 25 | $219.9M | $920.0M | ||
| Q2 25 | $89.0M | $1.0B | ||
| Q1 25 | $30.8M | $736.0M | ||
| Q4 24 | $47.1M | $941.0M | ||
| Q3 24 | $138.7M | $934.0M | ||
| Q2 24 | $107.1M | $952.0M | ||
| Q1 24 | $-82.3M | $198.0M |
自由现金流EXASL
| Q4 25 | $120.4M | $426.0M | ||
| Q3 25 | $190.0M | $764.0M | ||
| Q2 25 | $46.7M | $872.0M | ||
| Q1 25 | $-365.0K | $638.0M | ||
| Q4 24 | $10.7M | $767.0M | ||
| Q3 24 | $112.6M | $794.0M | ||
| Q2 24 | $71.2M | $793.0M | ||
| Q1 24 | $-120.0M | $39.0M |
自由现金流率EXASL
| Q4 25 | 13.7% | 51.5% | ||
| Q3 25 | 22.3% | 104.4% | ||
| Q2 25 | 5.8% | 113.4% | ||
| Q1 25 | -0.1% | 75.4% | ||
| Q4 24 | 1.5% | 97.2% | ||
| Q3 24 | 15.9% | 116.3% | ||
| Q2 24 | 10.2% | 111.5% | ||
| Q1 24 | -18.8% | 5.5% |
资本支出强度EXASL
| Q4 25 | 3.6% | 23.1% | ||
| Q3 25 | 3.5% | 21.3% | ||
| Q2 25 | 5.2% | 17.4% | ||
| Q1 25 | 4.4% | 11.6% | ||
| Q4 24 | 5.1% | 22.1% | ||
| Q3 24 | 3.7% | 20.5% | ||
| Q2 24 | 5.1% | 22.4% | ||
| Q1 24 | 5.9% | 22.4% |
现金转化率EXASL
| Q4 25 | — | 1.53× | ||
| Q3 25 | — | 1.83× | ||
| Q2 25 | — | 2.57× | ||
| Q1 25 | — | 1.99× | ||
| Q4 24 | — | 5.03× | ||
| Q3 24 | — | 2.33× | ||
| Q2 24 | — | 2.58× | ||
| Q1 24 | — | 0.43× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
EXAS
| Screening | $695.1M | 79% |
| Precision Oncology | $183.2M | 21% |
L
| Transportation And Storage Of Natural Gas And NG Ls And Ethane Supply And Transportation Services | $601.0M | 73% |
| Lodging And Related Services | $226.0M | 27% |
